Oxford Vacmedix UK Limited news

Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19

Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today that it will use its proprietary recombinant overlapping peptide (ROP) technology to develop a new vaccine and diagnostic tests for Covid-19. The research will be carried out in collaboration with the renowned Nuffield Department of Medicine (NDM) at the University of Oxford. The project aims to develop a low-cost vaccine with the potential to be used both as a prop

May. 12, 2020